Redx Joins Forces With Jounce To Form $425m Cancer And Fibrosis Company
Nabs NASDAQ Listing
After a rollercoaster of a journey to date, UK firm Redx unveiled plans to merge with US biotech Jounce in a deal that would create a $425m transatlantic company with a robust cash runway through to 2025.
